Induction of acute myeloid leukemia with idarubicin, cytarabine and cladribine

Eric Wiedower, Omer Jamy, Michael Martin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Daunorubicin and cytarabine has been the standard-of-care for induction therapy for acute myeloid leukemia (AML). Adding cladribine to daunorubicin (60 mg/m2) and cytarabine has increased complete remission (CR) rates and median overall survival (OS). However, the efficacy of adding cladribine to 7+3 with other anthracyclines is unknown. Patients and Methods: We retrospectively evaluated patients with AML receiving induction with idarubicin, cytarabine and cladribine (ICC) between 1/1/2010 and 06/30/2015 at the Methodist University Hospital in Memphis, Tennessee. Institutional Review Board approval was obtained for the study. Patient, disease characteristics and outcomes were analyzed with GraphPad Prism, Microsoft Excel and SPSSv19.0 software. Results: Twenty-four patients induced with ICC for AML were identified. Thirteen (54.2%) had at least one high-risk feature. Hypoplastic marrow was achieved in all by day 14; 19 (79.2%) achieved CR. Thirty-day mortality was 8.3%; 33-month OS and disease-free survival were 56% and 36%, respectively. Conclusion: Induction of AML with ICC was associated with a high CR rate and OS in our high-risk population.

Original languageEnglish (US)
Pages (from-to)6287-6290
Number of pages4
JournalAnticancer Research
Volume35
Issue number11
StatePublished - Jan 1 2015

Fingerprint

Idarubicin
Cladribine
Cytarabine
Acute Myeloid Leukemia
Daunorubicin
Survival
Research Ethics Committees
Anthracyclines
Standard of Care
Disease-Free Survival
Software
Survival Rate
Bone Marrow
Mortality
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Induction of acute myeloid leukemia with idarubicin, cytarabine and cladribine. / Wiedower, Eric; Jamy, Omer; Martin, Michael.

In: Anticancer Research, Vol. 35, No. 11, 01.01.2015, p. 6287-6290.

Research output: Contribution to journalArticle

Wiedower, Eric ; Jamy, Omer ; Martin, Michael. / Induction of acute myeloid leukemia with idarubicin, cytarabine and cladribine. In: Anticancer Research. 2015 ; Vol. 35, No. 11. pp. 6287-6290.
@article{aef697e6cc684cb183256b16f5dbfc4f,
title = "Induction of acute myeloid leukemia with idarubicin, cytarabine and cladribine",
abstract = "Background: Daunorubicin and cytarabine has been the standard-of-care for induction therapy for acute myeloid leukemia (AML). Adding cladribine to daunorubicin (60 mg/m2) and cytarabine has increased complete remission (CR) rates and median overall survival (OS). However, the efficacy of adding cladribine to 7+3 with other anthracyclines is unknown. Patients and Methods: We retrospectively evaluated patients with AML receiving induction with idarubicin, cytarabine and cladribine (ICC) between 1/1/2010 and 06/30/2015 at the Methodist University Hospital in Memphis, Tennessee. Institutional Review Board approval was obtained for the study. Patient, disease characteristics and outcomes were analyzed with GraphPad Prism, Microsoft Excel and SPSSv19.0 software. Results: Twenty-four patients induced with ICC for AML were identified. Thirteen (54.2{\%}) had at least one high-risk feature. Hypoplastic marrow was achieved in all by day 14; 19 (79.2{\%}) achieved CR. Thirty-day mortality was 8.3{\%}; 33-month OS and disease-free survival were 56{\%} and 36{\%}, respectively. Conclusion: Induction of AML with ICC was associated with a high CR rate and OS in our high-risk population.",
author = "Eric Wiedower and Omer Jamy and Michael Martin",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "35",
pages = "6287--6290",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - Induction of acute myeloid leukemia with idarubicin, cytarabine and cladribine

AU - Wiedower, Eric

AU - Jamy, Omer

AU - Martin, Michael

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Daunorubicin and cytarabine has been the standard-of-care for induction therapy for acute myeloid leukemia (AML). Adding cladribine to daunorubicin (60 mg/m2) and cytarabine has increased complete remission (CR) rates and median overall survival (OS). However, the efficacy of adding cladribine to 7+3 with other anthracyclines is unknown. Patients and Methods: We retrospectively evaluated patients with AML receiving induction with idarubicin, cytarabine and cladribine (ICC) between 1/1/2010 and 06/30/2015 at the Methodist University Hospital in Memphis, Tennessee. Institutional Review Board approval was obtained for the study. Patient, disease characteristics and outcomes were analyzed with GraphPad Prism, Microsoft Excel and SPSSv19.0 software. Results: Twenty-four patients induced with ICC for AML were identified. Thirteen (54.2%) had at least one high-risk feature. Hypoplastic marrow was achieved in all by day 14; 19 (79.2%) achieved CR. Thirty-day mortality was 8.3%; 33-month OS and disease-free survival were 56% and 36%, respectively. Conclusion: Induction of AML with ICC was associated with a high CR rate and OS in our high-risk population.

AB - Background: Daunorubicin and cytarabine has been the standard-of-care for induction therapy for acute myeloid leukemia (AML). Adding cladribine to daunorubicin (60 mg/m2) and cytarabine has increased complete remission (CR) rates and median overall survival (OS). However, the efficacy of adding cladribine to 7+3 with other anthracyclines is unknown. Patients and Methods: We retrospectively evaluated patients with AML receiving induction with idarubicin, cytarabine and cladribine (ICC) between 1/1/2010 and 06/30/2015 at the Methodist University Hospital in Memphis, Tennessee. Institutional Review Board approval was obtained for the study. Patient, disease characteristics and outcomes were analyzed with GraphPad Prism, Microsoft Excel and SPSSv19.0 software. Results: Twenty-four patients induced with ICC for AML were identified. Thirteen (54.2%) had at least one high-risk feature. Hypoplastic marrow was achieved in all by day 14; 19 (79.2%) achieved CR. Thirty-day mortality was 8.3%; 33-month OS and disease-free survival were 56% and 36%, respectively. Conclusion: Induction of AML with ICC was associated with a high CR rate and OS in our high-risk population.

UR - http://www.scopus.com/inward/record.url?scp=84946024043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946024043&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 6287

EP - 6290

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -